alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GLAMIS GOLD
LTD. CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30,
1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10-Q
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                          30,242
<SECURITIES>                                         0
<RECEIVABLES>                                    4,642
<ALLOWANCES>                                         0
<INVENTORY>                                     19,190
<CURRENT-ASSETS>                                54,544
<PP&E>                                         314,692
<DEPRECIATION>                                 201,882
<TOTAL-ASSETS>                                 175,980
<CURRENT-LIABILITIES>                            9,087
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       157,639
<OTHER-SE>                                     (8,123)
<TOTAL-LIABILITY-AND-EQUITY>                   175,980
<SALES>                                         38,427
<TOTAL-REVENUES>                                38,427
<CGS>                                           33,867
<TOTAL-COSTS>                                   50,346
<OTHER-EXPENSES>                               (1,919)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 266
<INCOME-PRETAX>                               (10,266)
<INCOME-TAX>                                   (1,302)
<INCOME-CONTINUING>                            (8,964)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (8,964)
<EPS-BASIC>                                   (0.14)
<EPS-DILUTED>                                   (0.14)


</TABLE>
§ 582.1500 Monoammonium glutamate. ( a ) *Product.* Monoammonium glutamate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
# C_2015389EN.01005701.xml

| 23.11.2015 | EN | Official Journal of the European Union | C 389/57 |
| --- | --- | --- | --- |

23.11.2015

EN

Official Journal of the European Union

C 389/57

---

Order of the General Court of 5 October 2015 — Grigoriadis and Others v Parliament and Others

(Case T-413/14) (1)

1

((Action for failure to act and for damages - Restructuring of the Greek public debt - Involvement of the private sector - Loss consisting in the reduction of sums owed - Statements by the Heads of State or Government of the euro area and the EU institutions - Eurogroup statement - Failure to specify the causal link with the loss pleaded - Inadmissibility))

(2015/C 389/65)

Language of the case: Greek

Parties

Parties

Applicants: Grigoris Grigoriadis (Athens, Greece), Faidra Grigoriadou (Athens), Ioannis Tsolias (Thessaloniki, Greece), Dimitrios Alexopoulos (Thessaloniki), Nikolaos Papageorgiou (Athens) and Ioannis Marinopoulos (Athens) (represented by: C. Papadimitriou, lawyer)

Applicants:

Defendants: European Parliament (represented by: A. Troupiotis and L. Visaggio, acting as Agents); European Council; Eurogroup; Council of the European Union (represented by: A. de Gregorio Merino and M. Balta, acting as Agents); European Commission (represented by: J.-P. Keppenne and M. Konstantinidis, acting as Agents); and European Central Bank (ECB) (represented by: P. Papapaschalis and P. Senkovic, acting as Agents)

Defendants:

Re:

Re:

First, an application for a declaration that the defendants unlawfully failed to act in order for the bonds held by the applicants not to be affected by the plan for private sector involvement in the debt financing programme (PSI), reducing the value of the Greek State’s debt, and second, an application seeking compensation for the loss allegedly suffered by the applicants following that unlawful failure to act.

Operative part of the order

Operative part of the order

| 1. | The action is dismissed. |
| --- | --- |

1.

The action is dismissed.

| 2. | Grigoris Grigoriadis, Faidra Grigoriadou, Ioannis Tsolias, Dimitrios Alexopoulos, Nikolaos Papageorgiou and Ioannis Marinopoulos shall pay the costs. |
| --- | --- |

2.

Grigoris Grigoriadis, Faidra Grigoriadou, Ioannis Tsolias, Dimitrios Alexopoulos, Nikolaos Papageorgiou and Ioannis Marinopoulos shall pay the costs.

---

(1)  OJ C 439, 8.12.2014.

1

---
##### 



Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER REQUIRED BY
RULE 13A-14(A) OR RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Richard Lau, certify that: 1. I have reviewed this annual report on Form 20-F of Deswell Industries, Inc. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the company as of, and for, the periods presented in this report; 4. The companys other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the company and have: (a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the company, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report
is being prepared; (b) Evaluated the effectiveness of the companys disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;
and (c) Disclosed in this report any change in the companys internal control over
financial reporting that occurred during the period covered by the annual report that has
materially affected, or is reasonably likely to materially affect, the companys internal
control over financial reporting; and 5. The companys other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the companys auditors and the audit
committee of the companys board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the companys ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who
have a significant role in the companys internal control over financial reporting. Date: July 8, 2005 /s/ Richard LauRichard LauChief Executive Officer
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.3825 Mechanical walker. ( a ) *Identification.* A mechanical walker is a four-legged device with a metal frame intended for medical purposes to provide moderate weight support while walking. It is used by disabled persons who lack strength, good balance, or endurance.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, regarding general requirements concerning records and § 820.198, regarding complaint files.
[48 FR 53047, Nov. 23, 1983, as amended at 66 FR 38817, July 25, 2001]
§ 640.64 Collection of blood for Source Plasma. ( a ) [Reserved]
( b ) *Blood containers.* Blood containers and donor sets must be pyrogen-free, sterile, and identified by lot number.
( c ) *The anticoagulant solution.* The anticoagulant solution must be sterile and pyrogen-free. Anticoagulant solutions must be compounded and used according to a formula that has been approved for the applicant by the Director, Center for Biologics Evaluation and Research.
( d ) *Donor identification.* Each unit of blood and plasma shall be so marked or identified by number or other symbol so as to relate it directly to the donor.
( e ) *Prevention of contamination of the blood and plasma.* The skin of the donor at the site of phlebotomy shall be prepared thoroughly and carefully by a method that gives maximum assurance of a sterile container of blood. The blood shall be collected, the plasma separated, and the cells returned to the donor by aseptic methods in a sterile system which may be closed, or may be vented if the vent protects the blood cells and plasma against contamination.
[38 FR 32089, Nov. 20, 1973; 39 FR 13632, Apr. 16, 1974, as amended at 41 FR 10768, Mar. 12, 1976; 49 FR 23834, June 8, 1984; 50 FR 4140, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 59 FR 49351, Sept. 28, 1994; 63 FR 16685, Apr. 6, 1998; 64 FR 56453, Oct. 20, 1999; 72 FR 45888, Aug. 16, 2007; 80 FR 29905, May 22, 2015]
**Exhibit 32**

## **CERTIFICATION**

**The undersigned certify pursuant to18 U.S.C. § 1350, that:**

(1)           The accompanying Quarterly Report on Form10-QSB for the period ended July 31, 2006 fullycomplies with the requirements of Section 13(a) or 15(d) of the Securities ExchangeAct of 1934; and

(2)           The information contained in the accompanying Reportfairly presents, in all material respects,the financial condition and results of operations of the Company.
| Date:  | September 11, 2006 |   | /s/ Rodney A. Young                   |   |
|--------|--------------------|--------|---------------------------------------|--------|
|   |               |   | Rodney A. Young                       |
|   |               |   | President and Chief Executive Officer |
|   |               |   |                                  |
|   |               |   |                                  |
| Date:  | September 11, 2006 |   | /s/ Dale H. Johnson                   |   |
|   |               |   | Dale H. Johnson                       |
|   |               |   | Chief Financial Officer               |

 

1

----
<TABLE> <S> <C>

<ARTICLE> CT
<CIK> 0000815024
<NAME> AMERICAN AFFORDABLE HOUSING II LIMITED PARTNERSHIP
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               JUN-30-1998
<TOTAL-ASSETS>                               2,921,921
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 2,921,921
<TOTAL-REVENUES>                                 7,611
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (215,178)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (207,567)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
**Exhibit 32**

 

 

## **CERTIFICATION**

 

**The undersigned certify pursuantto 18 U.S.C. § 1350, that:**

 

(1)                                The accompanying Quarterly Report on Form 10-QSB forthe period ended April 30, 2006fully complies with the requirements ofSection 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)                                The information contained in the accompanying Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 
| Date:  | June 14, 2006 |   |   |   |   |   | /s/  Rodney A. Young                   |
|--------|---------------|--------|--------|--------|--------|--------|----------------------------------------|
|   |          |   |   |   |   |   | Rodney A. Young                        |
|   |          |   |   |   |   |   | President  and Chief Executive Officer |

 

 
| Date:  | June 14, 2006 |   |   |   |   |   | /s/  Dale H. Johnson     |
|--------|---------------|--------|--------|--------|--------|--------|--------------------------|
|   |          |   |   |   |   |   | Dale  H. Johnson         |
|   |          |   |   |   |   |   | Chief  Financial Officer |

 

 

 

 

----
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.4150 Scalp clip. ( a ) *Identification.* A scalp clip is a plastic or metal clip used to stop bleeding during surgery on the scalp.
( b ) *Classification.* Class II (performance standards).
725 P.2d 829

#### In the Matter of Jose Luis ARRIETA, An Attorney Admitted to Practice Before the Courts of the State of New Mexico.

Disciplinary Proceeding No. 16402.

Supreme Court of New Mexico.

Sept. 30, 1986.

ORDER

This matter coming on for consideration by the Court upon Motion for Order to Show Cause, and Arrieta not appearing although the Order to Show Cause having been issued and served upon him, and the Court having heard argument of bar counsel and being sufficiently advised in the premises:

NOW, THEREFORE, IT IS ORDERED that JOSE LUIS ARRIETA is hereby held in contempt of this Court for his failure to comply with the Court’s orders of July 16, 1986, 722 P.2d 640, and September 8, 1986, and his failure to cooperate with the Disciplinary Board.

IT IS FURTHER ORDERED that the previous suspension of Arrieta for one year be increased to five years.

IT IS FURTHER ORDERED that Arrieta must comply in full with all previous orders of this Court, must comply with the requirements of NMSA 1978, Rules Governing Discipline, Rule 17 (Repl.Pamp. 1985), and must cooperate with the disciplinary authorities and all officers appointed by this Court.

IT IS FURTHER ORDERED that Arrieta is fined the sum of $50.00 for each day he remains in contempt of this Court after being served a copy of this Order.

IT IS FURTHER ORDERED that if Arrieta remains in contempt of this Court for ten (10) days after receiving a copy of this order, he will be disbarred from the practice of law pursuant to NMSA 1978, Rules Governing Discipline, Rule 11(g) (Order filed February 10, 1986; effective May 1, 1986).

*630IT IS FURTHER ORDERED that this Order be published in the State Bar of New Mexico *News and Views*and in the *New Mexico Reports.*

IT IS SO ORDERED.

WILLIAM RIORDAN, Chief Justice

DAN SOSA, Jr., Senior Justice

WILLIAM R. FEDERICI, Justice

HARRY E. STOWERS, Justice

WALTERS, J., not participating.
§ 900.25 Hearings and appeals. ( a ) Opportunities to challenge final adverse actions taken by FDA regarding approval of certification agencies or withdrawal of approval of certification agencies shall be communicated through notices of opportunity for informal hearings in accordance with part 16 of this chapter.
( b ) A facility that has been denied certification is entitled to an appeals process from the certification agency. The appeals process shall be specified in writing by the certification agency and shall have been approved by FDA in accordance with §§ 900.21 and 900.22.
[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Page 9909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4482]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel, Special Emphasis Panel Meeting, 
ZGM1 CBCB (SB).
    Date: March 26, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Hotel--Bethesda, Bethesda, MD 20814.
    Contact Person: Arthur L. Zachary, PhD, Scientific Review 
Officer, Office of Scientific Review, National Institute of General 
Medical Sciences, National Institutes of Health, Natcher Building, 
Room 3AN-12, Bethesda, MD 20892, (301) 594-2886, 
<a href="/cdn-cgi/l/email-protection#463c27252e27343f2706282f212b3568282f2e68212930"><span class="__cf_email__" data-cfemail="7a001b19121b08031b3a14131d170954141312541d150c">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: February 25, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4482 Filed 3-3-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4260 Cardiopulmonary bypass arterial line blood filter. ( a ) *Identification.* A cardiopulmonary bypass arterial line blood filter is a device used as part of a gas exchange (oxygenator) system to filter nonbiologic particles and emboli (blood clots or pieces of foreign material flowing in the bloodstream which will obstruct circulation by blocking a vessel) out of the blood. It is used in the arterial return line.
( b ) *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Arterial Line Blood Filter 510(k) Submissions.”
[45 FR 7907, Feb. 5, 1980, as amended at 52 FR 17737, May 11, 1987; 66 FR 18542, Apr. 10, 2001]
#### SHEBOYGAN MACHINE CO. *v.*BROOKS OIL CO. *et al.*

No. 8570.

May 12, 1932.

*791
      *William Brunson,*for plaintiff in error.

*C. ~C. Crockett*and *M. 3. Blaclcshear,*contra.

Per Curiam.

On the call of the case in this court a motion was made to dismiss the writ of error, on the ground that not all essential parties were made parties to the bill of exceptions and served. J. P. Harden was named as representative of a class of general creditors, but was not made a party to the bill of exceptions. The plaintiff in error amended the bill of exceptions in this court, by making J. P. Harden a party defendant thereto, and attached'to the motion to amend and tendered to the court a written acknowledgment and waiver of service and consent and agreement that the case be heard by this court, which was duly signed by J. P. Harden. In view of the above, the motion to dismiss on the ground stated is denied.

The exception is to a judgment appointing a receiver. The basis of the suit was that there was litigation consisting of a number of suits brought by creditors, one levy having already been made, and others threatened. The petition does not allege insolvency; on the contrary, it alleges facts which would negative insolvency. It is alleged that the defendant is a going concern; and that if the property be levied on piecemeal, it would dismember the manufacturing plant, and none of the creditors would realize anything on their debts. The judgment appointing a receiver must be reversed.

*Judgment reversed.*

*All the Justices concur, except Bussell, C. J., and Sill, J., who dissent, and Hines, J., absent for providential cause.*
March 10, 2003



PATCH ENERGY INC.

Suite 600 - 595 Hornby Street

Vancouver, B.C.   V6C 1A4

 

April 3, 2003

 

Fairchild International Corporation

Suite 600- 595 Hornby Street

Vancouver, B.C.

V6C 1A4

Dear Sirs:

Re:Participation Agreement dated February 10, 2003

(the "Participation Agreement")

Further to earlier communications with you, we confirm that Patch has now clarified the terms of its ongoing participation in the drilling of wells on the Farmout Lands (as that term is defined in the Participation Agreement).  In this regard, it has now been confirmed that Patch's ability to continue to earn a 12.5% interest in any wells drilled on the Farmout Lands is contingent upon Patch paying 15.625% of the costs associated with such wells.  Therefore, this letter will serve to confirm that, for good and valuation consideration, the receipt and sufficiency of which is acknowledged by you, it has been agreed to amend the terms of the Participation Agreement so that the reference to the "Costs" shall be to 2.5%, the costs associated with the Second Program (as that term is defined in the Participation Agreement).

We confirm that the Participation Agreement, as amended by this letter agreement, continues in full force and effect.

Accepting that the above accurately details your understanding of our agreement in this regard, would you please execute this letter where indicated and return same at your early convenience.

Yours truly,

PATCH ENERGY INC.

/s/ David Stadnyk

Per:

Authorized Signatory

ACKNOWLEDGED AND AGREED TO THIS 7TH DAY OF APRIL, 2003.

FAIRCHILD INTERNATIONAL CORPORATION

/s/ George Tsafalas

Per:

Authorized Signatory
#### State of Connecticut *v.*One 1966 Black Cadillac

*Charles Hanken,*for the appellee (defendant).

*Dennis F. Gaffney,*assistant chief prosecuting attorney, for the appellant (state).

Argued January 7

decided January *7,*1969

The motion by the defendant to dismiss the appeal from the Appellate Division of the Circuit Court is denied.
-84 -82 -80 -78 -76 -74 -72

 34

 36

 38

 40

★

▲

▲

▲

▲

★ ▲ ▲ ▲

▲

 500

 1000

 1500

 100

18 12 06 00

05/31

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 31 May 06

 EDAS Meteorological Data

Source

★ at 38.77 N 77.11 W Meters AGL
#### Brannan *et al. v.*Harrison, Comptroller-general, *et al.*

No. 9046.

June 16, 1932.

*O. N. Davie, J. F. Kemp, Lawrence 8. Camp,*and *J. D. Tindall,*for plaintiffs.

*George M. Napier, attorney-general, T. B. Gress, assistant attorney-general, Bobert 8. Sams, J. P. Wilhoit,*and *Bobert B. Trout-man,*for defendants.

Beck, P. J.

Under the decision and rulings made in the case of *Brannan*v. *Harrison,*172 *Ga.*669 (158 S. E. 319), the court did not err in directing a verdict for the defendants, and in overruling the plaintiffs’ motion for a new trial.

*Judgment affirmed.*

*Russell, G. J., and Hill and Gilbert, JJ., concur. Atkinson, J., dissents.*